Main variables	No. of employees	Total
No. of companies carrying out R&D in Biotechnology	Fewer than 250 employees	1.010
No. of companies carrying out R&D in Biotechnology	250 or more employees	69
No. of companies carrying out R&D in Biotechnology	Total	1.078
%Companies according to biotechnology used: Genetic code	Fewer than 250 employees	34
%Companies according to biotechnology used: Genetic code	250 or more employees	49
%Companies according to biotechnology used: Genetic code	Total	35
%Companies according to biotechnology used: Functional units	Fewer than 250 employees	41
%Companies according to biotechnology used: Functional units	250 or more employees	54
%Companies according to biotechnology used: Functional units	Total	42
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Fewer than 250 employees	25
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	250 or more employees	48
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Total	27
%Companies according to biotechnology used: Bioprocesses	Fewer than 250 employees	48
%Companies according to biotechnology used: Bioprocesses	250 or more employees	59
%Companies according to biotechnology used: Bioprocesses	Total	49
%Companies according to biotechnology used: Sub-cellular organisms	Fewer than 250 employees	7
%Companies according to biotechnology used: Sub-cellular organisms	250 or more employees	12
%Companies according to biotechnology used: Sub-cellular organisms	Total	8
%Companies according to biotechnology used: Bio-computing	Fewer than 250 employees	22
%Companies according to biotechnology used: Bio-computing	250 or more employees	22
%Companies according to biotechnology used: Bio-computing	Total	22
%Companies according to biotechnology used: Nanobiotechnology	Fewer than 250 employees	14
%Companies according to biotechnology used: Nanobiotechnology	250 or more employees	18
%Companies according to biotechnology used: Nanobiotechnology	Total	14
%Companies according to biotechnology used: Other	Fewer than 250 employees	12
%Companies according to biotechnology used: Other	250 or more employees	8
%Companies according to biotechnology used: Other	Total	12
Companies in which biotechnology activities are: Main and/or exclusive	Fewer than 250 employees	511
Companies in which biotechnology activities are: Main and/or exclusive	250 or more employees	15
Companies in which biotechnology activities are: Main and/or exclusive	Total	526
Companies in which biotechnology activities are: A secondary line of business	Fewer than 250 employees	155
Companies in which biotechnology activities are: A secondary line of business	250 or more employees	18
Companies in which biotechnology activities are: A secondary line of business	Total	173
Companies in which biotechnology activities are: A tool necessary for production	Fewer than 250 employees	344
Companies in which biotechnology activities are: A tool necessary for production	250 or more employees	35
Companies in which biotechnology activities are: A tool necessary for production	Total	379
%Company by field(s) of ultimate application of biotechnology use: Human Health	Fewer than 250 employees	48
%Company by field(s) of ultimate application of biotechnology use: Human Health	250 or more employees	50
%Company by field(s) of ultimate application of biotechnology use: Human Health	Total	48
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Fewer than 250 employees	21
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	250 or more employees	5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Total	20
%Company by field(s) of ultimate application of biotechnology use: Food products	Fewer than 250 employees	32
%Company by field(s) of ultimate application of biotechnology use: Food products	250 or more employees	36
%Company by field(s) of ultimate application of biotechnology use: Food products	Total	33
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Fewer than 250 employees	24
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	250 or more employees	21
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Total	24
%Company by field(s) of ultimate application of biotechnology use: Environment	Fewer than 250 employees	15
%Company by field(s) of ultimate application of biotechnology use: Environment	250 or more employees	15
%Company by field(s) of ultimate application of biotechnology use: Environment	Total	15
%Company by field(s) of ultimate application of biotechnology use: Industry	Fewer than 250 employees	14
%Company by field(s) of ultimate application of biotechnology use: Industry	250 or more employees	6
%Company by field(s) of ultimate application of biotechnology use: Industry	Total	14
Personnel in R&D in biotechnology (no. of persons)	Fewer than 250 employees	7.849
Personnel in R&D in biotechnology (no. of persons)	250 or more employees	2.342
Personnel in R&D in biotechnology (no. of persons)	Total	10.191
Personnel in R&D in biotechnology (no. of persons): Researchers	Fewer than 250 employees	4.469
Personnel in R&D in biotechnology (no. of persons): Researchers	250 or more employees	1.305
Personnel in R&D in biotechnology (no. of persons): Researchers	Total	5.774
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	Fewer than 250 employees	3.380
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	250 or more employees	1.037
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	Total	4.417
Personnel in R&D in biotechnology (no. of persons): women	Fewer than 250 employees	4.199
Personnel in R&D in biotechnology (no. of persons): women	250 or more employees	1.326
Personnel in R&D in biotechnology (no. of persons): women	Total	5.525
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	Fewer than 250 employees	2.320
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	250 or more employees	695
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	Total	3.015
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	Fewer than 250 employees	1.879
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	250 or more employees	631
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	Total	2.511
Personnel in R&D in biotechnology (FTE)	Fewer than 250 employees	5.530,1
Personnel in R&D in biotechnology (FTE)	250 or more employees	1.661,2
Personnel in R&D in biotechnology (FTE)	Total	7.191,4
Personnel in R&D in biotechnology (FTE): Researchers	Fewer than 250 employees	3.333
Personnel in R&D in biotechnology (FTE): Researchers	250 or more employees	943,6
Personnel in R&D in biotechnology (FTE): Researchers	Total	4.276,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants	Fewer than 250 employees	2.197,1
Personnel in R&D in biotechnology (FTE): Technicians and assistants	250 or more employees	717,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants	Total	2.914,7
Personnel in R&D in biotechnology (FTE): women	Fewer than 250 employees	3.061
Personnel in R&D in biotechnology (FTE): women	250 or more employees	924,4
Personnel in R&D in biotechnology (FTE): women	Total	3.985,4
Personnel in R&D in biotechnology (FTE): (women) Researchers	Fewer than 250 employees	1.742,1
Personnel in R&D in biotechnology (FTE): (women) Researchers	250 or more employees	491,9
Personnel in R&D in biotechnology (FTE): (women) Researchers	Total	2.234
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	Fewer than 250 employees	1.318,9
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	250 or more employees	432,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	Total	1.751,4
Internal expenditure on R&D (thousands of euros)	Fewer than 250 employees	441.736
Internal expenditure on R&D (thousands of euros)	250 or more employees	136.435
Internal expenditure on R&D (thousands of euros)	Total	578.171
1) By nature of the expense: Current expenses	Fewer than 250 employees	387.035
1) By nature of the expense: Current expenses	250 or more employees	130.565
1) By nature of the expense: Current expenses	Total	517.601
1.1) Remuneration to researchers	Fewer than 250 employees	158.420
1.1) Remuneration to researchers	250 or more employees	55.335
1.1) Remuneration to researchers	Total	213.755
1.2) Remuneration to technicians and assistants	Fewer than 250 employees	74.027
1.2) Remuneration to technicians and assistants	250 or more employees	24.413
1.2) Remuneration to technicians and assistants	Total	98.440
1.3) Other current expenses	Fewer than 250 employees	154.588
1.3) Other current expenses	250 or more employees	50.818
1.3) Other current expenses	Total	205.406
2) By nature of the expense: Capital expenses	Fewer than 250 employees	54.701
2) By nature of the expense: Capital expenses	250 or more employees	5.870
2) By nature of the expense: Capital expenses	Total	60.570
2.1) Land and buildings	Fewer than 250 employees	22.554
2.1) Land and buildings	250 or more employees	54
2.1) Land and buildings	Total	22.609
2.2) Equipment and instruments	Fewer than 250 employees	30.685
2.2) Equipment and instruments	250 or more employees	5.483
2.2) Equipment and instruments	Total	36.169
2.3) Acquisition of specific R&D software	Fewer than 250 employees	1.461
2.3) Acquisition of specific R&D software	250 or more employees	332
2.3) Acquisition of specific R&D software	Total	1.793
1) By origin of the funds: National funds	Fewer than 250 employees	379.550
1) By origin of the funds: National funds	250 or more employees	108.064
1) By origin of the funds: National funds	Total	487.615
1.1) Own funds	Fewer than 250 employees	249.390
1.1) Own funds	250 or more employees	81.068
1.1) Own funds	Total	330.459
1.2) From companies	Fewer than 250 employees	32.831
1.2) From companies	250 or more employees	12.630
1.2) From companies	Total	45.462
1.3) Public Administration funds	Fewer than 250 employees	53.162
1.3) Public Administration funds	250 or more employees	13.028
1.3) Public Administration funds	Total	66.189
1.4) From Universities	Fewer than 250 employees	25.148
1.4) From Universities	250 or more employees	.
1.4) From Universities	Total	25.148
1.5) From non profit private institutions	Fewer than 250 employees	19.019
1.5) From non profit private institutions	250 or more employees	1.338
1.5) From non profit private institutions	Total	20.357
1) By origin of the funds: Foreign funds	Fewer than 250 employees	62.186
1) By origin of the funds: Foreign funds	250 or more employees	28.371
1) By origin of the funds: Foreign funds	Total	90.556
2.1) From EU programmes	Fewer than 250 employees	18.782
2.1) From EU programmes	250 or more employees	2.150
2.1) From EU programmes	Total	20.932
2.2) Other foreign funds	Fewer than 250 employees	43.403
2.2) Other foreign funds	250 or more employees	26.221
2.2) Other foreign funds	Total	69.624
Purchase of R&D services in biotechnology (thousands of euros)	Fewer than 250 employees	111.514
Purchase of R&D services in biotechnology (thousands of euros)	250 or more employees	54.508
Purchase of R&D services in biotechnology (thousands of euros)	Total	166.022
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Fewer than 250 employees	67.448
Purchase of R&D services in biotechnology (thousands of euros): In Spain	250 or more employees	30.007
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Total	97.455
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Fewer than 250 employees	44.065
Purchase of R&D services in biotechnology (thousands of euros): Abroad	250 or more employees	24.501
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Total	68.567
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Fewer than 250 employees	47
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	250 or more employees	30
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Total	46
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Fewer than 250 employees	13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	250 or more employees	12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Total	13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Fewer than 250 employees	14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	250 or more employees	16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Total	14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Fewer than 250 employees	14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	250 or more employees	13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Total	14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Fewer than 250 employees	18
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	250 or more employees	14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Total	17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Fewer than 250 employees	17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	250 or more employees	12
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Total	17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Fewer than 250 employees	18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	250 or more employees	17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Total	18
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Fewer than 250 employees	35
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	250 or more employees	36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Total	35
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Fewer than 250 employees	50
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	250 or more employees	34
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Total	49
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Fewer than 250 employees	22
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	250 or more employees	9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Total	21
% Companies that have requested biotechnology patents in Biotechnology	Fewer than 250 employees	15
% Companies that have requested biotechnology patents in Biotechnology	250 or more employees	21
% Companies that have requested biotechnology patents in Biotechnology	Total	15
Number of patents requested	Fewer than 250 employees	451
Number of patents requested	250 or more employees	75
Number of patents requested	Total	526
% Companies with income of an international origin related to biotechnological activities	Fewer than 250 employees	26,4
% Companies with income of an international origin related to biotechnological activities	250 or more employees	19,1
% Companies with income of an international origin related to biotechnological activities	Total	26
% Turnover representing income of an international origin related to biotechnological activities	Fewer than 250 employees	6,5
% Turnover representing income of an international origin related to biotechnological activities	250 or more employees	0,8
% Turnover representing income of an international origin related to biotechnological activities	Total	1,4
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Fewer than 250 employees	51,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	250 or more employees	76,3
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Total	63,8
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Fewer than 250 employees	48,4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	250 or more employees	23,7
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Total	36,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Fewer than 250 employees	85,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	250 or more employees	97,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Total	91,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Fewer than 250 employees	1,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 or more employees	0,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	0,9
% Income of an international origin related with activities according to the classification: Operating source abroad	Fewer than 250 employees	3
% Income of an international origin related with activities according to the classification: Operating source abroad	250 or more employees	0,7
% Income of an international origin related with activities according to the classification: Operating source abroad	Total	1,9
% Income of an international origin related with activities according to the classification: Other	Fewer than 250 employees	10,1
% Income of an international origin related with activities according to the classification: Other	250 or more employees	1,1
% Income of an international origin related with activities according to the classification: Other	Total	5,6